Phylodynamics of Human Metapneumovirus and Evidence for a Duplication–Deletion Model in G-Gene Variant Evolution

Stephanie Goya [1], Ethan B. Nunley [1], Preston C. Longley [1], Jamie R. Mathis [2], Christina G. Varela [1], Da Yae Kim [1], Marc Nurik [2], Samia N. Naccache [2], Alexander L. Greninger [1,3,#]

Affiliations:

[1] Department of Laboratory Medicine and Pathology, University of Washington, 850 Republican St, 98109, Seattle, WA, USA
[2] Labcorp Seattle, Microbiology Department, 550 17th Ave #200, Seattle, WA 98122, USA
[3] Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, 98109, Seattle, WA, USA

[#]Corresponding author.
Phone number: 415-439-3448
Fax number: 206-616-4340
Email address: agrening@uw.edu

Word count: 1201 words

Abstract

Background: In December 2024, human metapneumovirus (hMPV) gained global attention amid rising cases in Chinese hospitals, prompting a World Health Organization (WHO) statement indicating case numbers remained within expected ranges. To assess whether a variant of public health concern was emerging and to examine global hMPV phylodynamics, we conducted a genomic surveillance study in western Washington State.

Study design: We sequenced hMPV genomes from inpatient and outpatient samples collected between 2021–2025 in western Washington State and constructed phylogenomic and phylodynamic trees.

Results: We obtained 60 hMPV-A and 39 hMPV-B genomes, including 13 from November 2024–January 2025. Following COVID-19 pandemic disruptions, hMPV seasonality returned to typical patterns after 2023. Genomic analysis showed hMPV-A predominance since 2022–23, with co-circulation of A2b1, A2b2, B1, and B2 sublineages. The A2b2 sublineage was most prevalent and all genomes carried a 111-nt G gene duplication. Phylogenetic evidence suggests the 111-nt variant evolved from a prior 180-nt duplication via a 69-nt deletion, rather than through independent duplication events. Most sublineages showed multiple co-circulating clades, except A2b1. Phylodynamics showed recovery of global diversity after pandemic-related declines and a higher evolutionary rate in hMPV-A compared to hMPV-B. No distinct evolutionary features of heightened concern were detected.

Conclusions: Despite recent concerns, our findings indicate that hMPV circulation in the USA follows expected seasonal patterns, with ongoing introductions of diverse viral variants from preexisting sublineages rather than emergence of a novel variant. Continued genomic surveillance is essential, particularly as vaccine development progresses.

Keywords

Human metapneumovirus, hMPV, genomics, USA, epidemiology, surveillance

Highlights

- hMPV seasonality in Washington State normalized by 2023 after pandemic-related disruption.
- Recent hMPV genomes show multiple introductions without evidence of a novel variant of concern.
- A2b2-111, the dominant sublineage, likely evolved from A2b2-180 variant via 69-nt G gene deletion.
- hMPV-A evolves faster than hMPV-B; global diversity declined in 2020 and rebounded post-2021.

Short Communication

Title: Phylodynamics of Human Metapneumovirus and Evidence for a Duplication–Deletion Model in G-Gene Variant Evolution

Background

In December 2024, human metapneumovirus (hMPV) gained international attention due to concerns over increases in cases in Chinese hospitals, prompting a World Health Organization (WHO) statement indicating case numbers were within expected ranges [1]. Discovered in 2001, hMPV is a seasonal respiratory virus spread through direct contact from fomites or aerosols, typically causing mild respiratory illness but potentially severe bronchiolitis and pneumonia, especially in infants, the elderly, and immunocompromised individuals [2]. In hematopoietic stem cell transplant patients, hMPV may lead to rapid respiratory failure and death in up to 27% of cases [3]. hMPV remains a global health threat, causing an estimated 643,000 annual hospitalizations and 7,700 deaths in children under 5 [4]. Treatment is supportive, as no licensed antivirals exist, though development of a combined mRNA vaccine for hMPV and respiratory syncytial virus (RSV) in children is underway [5,6].

hMPV is a negative-sense, single-stranded RNA virus with an approximately 13,000 nt genome encoding nine proteins, including fusion (F) and attachment (G) surface glycoproteins, which play key roles in viral entry and immune evasion. hMPV has two antigenic lineages, hMPV-A and hMPV-B, categorized into six phylogenetic sublineages: A1, A2a, A2b1, A2b2, B1, and B2 [7]. Interestingly, two independent nucleotide duplications have been reported in the same region of the G-gene in the A2b2 sublineage, resulting in 180nt (A2b2-180) and 111nt (A2b2-111) duplication variants [8,9]. However, hMPV genomic epidemiology and evolution dynamics remain extremely limited; only 21 hMPV genomes from 2024 were deposited in NCBI GenBank (Figure 1A). To identify whether hMPV is undergoing emergence of a variant of concern for public health, we conducted genomic surveillance in western Washington State (a region notable for early SARS-CoV-2 detection from China) alongside a global characterization of hMPV evolution over the last decade.

Study design

85 We sequenced hMPV genomes from deidentified remnant samples collected from inpatients and outpatients in
86 western Washington State (2021-2025). Samples tested positive from BioFire® RP2.1 (LabCorp Seattle) or Hologic
87 Panther® Fusion (University of Washington Virology). BioFire®-tested samples were quantitated using a hMPV RT-
88 qPCR [10]. Samples with cycle threshold (Ct) < 33 were selected to increase the likelihood of genome recovery.
89 This study was approved by the University of Washington IRB (STUDY00000408, STUDY00000885).
90
91 RNA was extracted using the Roche MagNA® Pure 96. Sequencing libraries were prepared with Illumina®
92 Respiratory Virus Enrichment Kit or QIAseq® xHYB Respiratory Panel and sequenced on an Illumina
93 NextSeq®2000 or NovaSeq®6000. Viral genomes were assembled using the REVICA-STRM pipeline
94 (https://github.com/greninger-lab/REVICA-STRM). Consensus genomes and raw reads were deposited in NCBI
95 under BioProject PRJNA1027483 (Supplementary Table 1).
96
97 We incorporated global hMPV genomes from NCBI GenBank (as of January 10, 2025) filtered for human-derived
98 sequences (7-15kb length, <20% N), yielding 513 hMPV-A and 456 hMPV-B genomes. Alignments were
99 performed with MAFFT v7.511 and phylogenies inferred using IQ-TREE v2.2 with SH-alrt and UFBoot2 support
100 [11,12]. Phylodynamic analysis used BEAST 2.7.6 with an uncorrelated relaxed clock and Extended Bayesian
101 Skyline model, with convergence assessed in Tracer v1.7 [13]. Maximum clade credibility trees (MCCT) were
102 summarized with TreeAnnotator, considering clades with posterior probabilities ≥ 0.8 as supported [14].
103
104 To investigate A2b2 G-gene duplication history, we inferred expanded G gene and F gene phylogenies using an
105 additional 945 A2b2 F gene and 1,494 G gene sequences from NCBI GenBank. Tree files and R markdown code are
106 available at https://github.com/greninger-lab/MPV_genomics. Full methods are described in Supplementary
107 Material.
108
109 **Results**
110 We obtained 99 hMPV genomes (60 hMPV-A and 39 hMPV-B), including 13 recent hMPV from November 2024–
111 January 2025 (Table 1, Figure 1A). Hospital-based surveillance revealed disrupted hMPV seasonality in Washington
112 State in 2020, with no outbreak in 2021. A delayed outbreak peaked in mid-2022 at 11.6% test positivity, followed

by a typical season in 2023 with increased positivity (14.6%) but returning to expected levels (9%) in the 2024 season (Figure 1B). Since 2022-23, hMPV-A predominated, with A2b2-111 the most frequent sublineage (Figure 1B). No significant differences in patient age or gender were observed across outbreaks or sublineages (G-test, $p > 0.1$).

Phylodynamic analysis showed genetically diverse recent hMPV strains are associated with multiple introductions into Washington State (Figures 1C). An exception was A2b1, where post-2020 strains clustered monophyletically. Global hMPV diversity (measured as effective population size) declined during 2020, likely reflecting pandemic-related transmission bottlenecks, with recovery after 2021 in hMPV-B and then hMPV-A (Figure 1D). Estimated evolutionary rate was higher for hMPV-A (1.11×10^{-3} substitutions/site/year, 95% High Posterior Density: 1.03×10^{-3} - 1.19×10^{-3}) than hMPV-B (8.93×10^{-4} substitutions/site/year, 95% HPD: 7.69×10^{-4} - 1.02×10^{-3}) (Figure 1E). However, no rate differences were observed among sublineages (Figure 1C) or pre-/post-2020 clades (Supplementary Material).

Time-scaled phylogenies suggest hMPV-A and hMPV-B have circulated for approximately 74 and 86 years, respectively (Figure 1C). The most prevalent sublineage currently, A2b2, has circulated since 2002. However, all post-2020 A2b2 strains carried a 111-nt G-gene duplication. To provide more resolution to the A2b2 history, expanded G-gene phylogeny revealed that A2b2-180 variant emerged first, and then the A2b2-111 variant diverged from the A2b2-180 clade (Figure 1F, Supplementary Figure 1). This pattern remained consistent after trimming the duplication copy from the G-gene alignment to control for artifacts (Supplementary Figure 2). Analysis of the alignment suggested A2b2-111 may have arisen via a 69-nt deletion from the A2b2-180 variant, rather than through independent duplication events (Figure 1G). Analysis of hMPV sequences derived from only complete genomes or expanded F-gene phylogeny was consistent with either successive duplication-deletion or independent duplication events (Figure 1C, Supplementary Figure 3). Nucleotide similarity also indicates that A2b2-111 is more similar to A2b2-180 strains (96.4%, IQR: 95.6-97%) than that original A2b2 strains (94.7%, IQR: 93.6-95.5%) (Supplementary Material).

Discussion

Despite increasing global awareness of hMPV outbreaks, genomic epidemiology remains very limited with 82% of available genomes from the last five years originating from the USA. Containment measures during the COVID-19 pandemic disrupted hMPV transmission globally, causing reduced circulation, diminished viral diversity, and altered seasonality. In Washington State, seasonality returned to pre-pandemic patterns (season from January to June) by 2023-24, aligning with national surveillance data, including a delayed 2022 outbreak and increased positivity rate during 2023 [15].

Phylodynamic analysis showed that hMPV-A is evolving faster than hMPV-B. Although hMPV has been circulating for over 70 years, all current hMPV genomes belong to four sublineages (A2b1, A2b2, B1, B2). Post-2020 most sublineages showed multiple co-circulating clades, except A2b1. A2b2 was dominant in our study, with all recent strains carrying a 111-nt G gene duplication [7,16]. While prior studies described the 111-nt and 180-nt duplications as independent evolutionary events, our complete G-gene phylogeny suggests a duplication-deletion model, in which the A2b2-111 variant arose from a 69-nt deletion of the A2b2-180 variant. Nucleotide similarity and tree structure support this model and may reflect selective pressures balancing immune evasion and structural fitness.

In summary, pandemic-related containment measures significantly affected hMPV transmission and diversity, though the virus has since recovered historical seasonality. Although currently circulating strains of hMPV do not exhibit any distinctive genomic features that warrant heightened concern, seasonal circulation and continuous evolution should be monitored closely, especially as vaccine trials are underway. Limitations in our study include a sample set biased toward high viral loads and lack of clinical outcome data. Expanded surveillance, including clinical metadata and broader geographic sampling is needed to better understand hMPV evolution and its implications for public health.

Acknowledgments.

ALG reports contract testing from Abbott, Cepheid, Novavax, Pfizer, Janssen, and Hologic, outside of the described work. All the other authors declare no conflict of interest. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

CRediT authorship contribution statement.

Conceptualization (SG, ALG), Methodology & Resources (EBT, PCL, JRM, CGV, DYK, MK), Data curation & Formal analysis (SG, EBT, PCL, JRM), Funding acquisition (SNN, ALG), Validation (SNN, ALG), Writing – original draft (SG, ALG), Writing – review and editing (all authors).

References

[1] World Health Organization, Trends of acute respiratory infection, including human metapneumovirus, in the Northern Hemisphere., Disease Outbreak News (2025). https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON550.

[2] N. Shafagati, J. Williams, Human metapneumovirus - what we know now, F1000Res 7 (2018) 135. https://doi.org/10.12688/f1000research.12625.1.

[3] D.P. Shah, P.K. Shah, J.M. Azzi, F. El Chaer, R.F. Chemaly, Human metapneumovirus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review, Cancer Lett 379 (2016) 100−106. https://doi.org/10.1016/j.canlet.2016.05.035.

[4] X. Wang, Y. Li, M. Deloria-Knoll, S.A. Madhi, C. Cohen, A. Ali, S. Basnet, Q. Bassat, W.A. Brooks, M. Chittaganpitch, M. Echavarria, R.A. Fasce, D. Goswami, S. Hirve, N. Homaira, S.R.C. Howie, K.L. Kotloff, N. Khuri-Bulos, A. Krishnan, M.G. Lucero, S. Lupisan, A. Mira-Iglesias, D.P. Moore, C. Moraleda, M. Nunes, H. Oshitani, B.E. Owor, F.P. Polack, K.L. O′Brien, Z.A. Rasmussen, B.A. Rath, V. Salimi, J.A.G. Scott, E.A.F. Simões, T.A. Strand, D.M. Thea, F.K. Treurnicht, L.C. Vaccari, L.-M. Yoshida, H.J. Zar, H. Campbell, H. Nair, Respiratory Virus Global Epidemiology Network, Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018: a systematic review and modelling study, Lancet Glob Health 9 (2021) e33−e43. https://doi.org/10.1016/S2214-109X(20)30393-4.

[5] ModernaTX, Inc., A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months, clinicaltrials.gov, 2024. https://clinicaltrials.gov/study/NCT05743881.

[6] D. Ogonczyk-Makowska, P. Brun, C. Vacher, C. Chupin, C. Droillard, J. Carbonneau, E. Laurent, V. Dulière, A. Traversier, O. Terrier, T. Julien, M. Galloux, S. Paul, J.-F. Eléouët, J. Fouret, M.-E. Hamelin, A. Pizzorno,

197 G. Boivin, M. Rosa-Calatrava, J. Dubois, Mucosal bivalent live attenuated vaccine protects against human
198 metapneumovirus and respiratory syncytial virus in mice, Npj Vaccines 9 (2024) 111.
199 https://doi.org/10.1038/s41541-024-00899-9.
200 [7] K. Groen, S. van Nieuwkoop, A. Meijer, B. van der Veer, J.J.A. van Kampen, P.L. Fraaij, R.A.M. Fouchier,
201 B.G. van den Hoogen, Emergence and Potential Extinction of Genetic Lineages of Human Metapneumovirus
202 between 2005 and 2021, mBio 14 (2022) e02280-22. https://doi.org/10.1128/mbio.02280-22.
203 [8] M. Saikusa, N. Nao, C. Kawakami, S. Usuku, T. Sasao, T. Toyozawa, M. Takeda, I. Okubo, A novel 111-
204 nucleotide duplication in the G gene of human metapneumovirus, Microbiol Immunol 61 (2017) 507–512.
205 https://doi.org/10.1111/1348-0421.12543.
206 [9] M. Saikusa, C. Kawakami, N. Nao, M. Takeda, S. Usuku, T. Sasao, K. Nishimoto, T. Toyozawa, 180-
207 Nucleotide Duplication in the G Gene of Human metapneumovirus A2b Subgroup Strains Circulating in
208 Yokohama City, Japan, since 2014, Front Microbiol 8 (2017) 402. https://doi.org/10.3389/fmicb.2017.00402.
209 [10] G.A. Weinberg, K.C. Schnabel, D.D. Erdman, M.M. Prill, M.K. Iwane, L.M. Shelley, B.L. Whitaker, P.G.
210 Szilagyi, C.B. Hall, Field evaluation of TaqMan Array Card (TAC) for the simultaneous detection of multiple
211 respiratory viruses in children with acute respiratory infection, J Clin Virol 57 (2013) 254–260.
212 https://doi.org/10.1016/j.jcv.2013.03.016.
213 [11] K. Katoh, K. Misawa, K. Kuma, T. Miyata, MAFFT: a novel method for rapid multiple sequence alignment
214 based on fast Fourier transform, Nucleic Acids Research 30 (2002) 3059–3066.
215 https://doi.org/10.1093/nar/gkf436.
216 [12] B.Q. Minh, H.A. Schmidt, O. Chernomor, D. Schrempf, M.D. Woodhams, A. von Haeseler, R. Lanfear, IQ-
217 TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era, Molecular
218 Biology and Evolution 37 (2020) 1530–1534. https://doi.org/10.1093/molbev/msaa015.
219 [13] A. Rambaut, A.J. Drummond, D. Xie, G. Baele, M.A. Suchard, Posterior Summarization in Bayesian
220 Phylogenetics Using Tracer 1.7, Systematic Biology 67 (2018) 901–904.
221 https://doi.org/10.1093/sysbio/syy032.
222 [14] R. Bouckaert, T.G. Vaughan, J. Barido-Sottani, S. Duchêne, M. Fourment, A. Gavryushkina, J. Heled, G.
223 Jones, D. Kühnert, N.D. Maio, M. Matschiner, F.K. Mendes, N.F. Müller, H.A. Ogilvie, L. du Plessis, A.
224 Popinga, A. Rambaut, D. Rasmussen, I. Siveroni, M.A. Suchard, C.-H. Wu, D. Xie, C. Zhang, T. Stadler, A.J.

Drummond, BEAST 2.5: An advanced software platform for Bayesian evolutionary analysis, PLOS Computational Biology 15 (2019) e1006650. https://doi.org/10.1371/journal.pcbi.1006650.

[15] N.B. Jobe, E. Rose, A.K. Winn, L. Goldstein, Z.D. Schneider, B.J. Silk, Human Metapneumovirus Seasonality and Co-Circulation with Respiratory Syncytial Virus - United States, 2014-2024, MMWR Morb Mortal Wkly Rep 74 (2025) 182−187. https://doi.org/10.15585/mmwr.mm7411a1.

[16] X. Min, Y. Wang, X. Dong, X. Dong, N. Wang, Z. Wang, L. Shi, Epidemiological characteristics of human metapneumovirus among children in Nanjing, China, Eur J Clin Microbiol Infect Dis 43 (2024) 1445−1452. https://doi.org/10.1007/s10096-024-04858-z.

235 **Table. Demographic and epidemiological details of hMPV genomic surveillance in Washington State.**

236

	hMPV-A	hMPV-B
Total (n = 99)	60	39
2021-2022	0	3
2022-2023	32	20
2023-2024	21	10
2024-2025	7	6
Age Group (n = 94)		
<5 years old	10	5
5 - 18 years old	5	3
19 - 65 years old	31	17
>65 years old	13	10
Sex (n= 94)		
Female	38	18
Male	21	17
hMPV median Ct value [IQR]	25.30 [7.05]	24.12 [4.67]
Clinical Status (n = 69)		
Outpatient	32	17
Inpatient	12	8

237

238

239 **Figure Legend**

240 **Figure. Human metapneumovirus genomic epidemiology.** A) Number of hMPV genomes in NCBI GenBank by
241 year, grouped by lineage (hMPV-A and hMPV-B). New Washington State (WA) genomes are shown in darker
242 shades. B) Top: Biweekly hMPV positivity rates from UW Medicine (2018–2025). Solid line indicates observed
243 positivity; dashed line represents expected seasonal pattern [17]. Background color shows total tests; the dotted box
244 marks the study period. Bottom: Monthly frequency of WA hMPV sublineages; total genome count is shown atop
245 each bar. C) Time-scaled Bayesian phylogenies of hMPV-A and hMPV-B. Sublineages are colored; WA genomes
246 marked with dots. Dashed vertical line indicates 2020. Left: number of genomes, median evolutionary rate
247 (substitutions/site/year), and interquartile range per sublineage. Scale: substitutions/site/year. D) Extended Bayesian
248 skyline plots of hMPV-A and hMPV-B diversity pre- and post-COVID-19, based on analysis shown in panel C. E)
249 Evolutionary rates of hMPV-A and hMPV-B. Box plots show median (horizontal line), 95% HPD interval (box),
250 and full range (whiskers). F) Maximum-likelihood tree of A2b2 G-gene sequences. Branches are colored by
251 sublineage; SH-aLRT/ultrafast bootstrap support shown for key nodes. Legend indicates sequence counts. G)
252 Models of A2b2 G-gene duplication origins. Left: "Independent duplications" model proposes independent event
253 emergence of 180-nt and 111-nt variants. Right: "Duplication–deletion" model suggests A2b2-111 arose via a 69-nt
254 deletion from A2b2-180.


A
Available hMPV genomes
hMPV-A
hMPV-A (WA)
hMPV-B
hMPV-B (WA)
Collection Date
B
hMPV positive cases (%)
Tested samples
observed
expected
Sublineage
B1
B2
A2b1
A2b2 111dup
Sublineage frequency
C
hMPV-A
hMPV genomes from WA
n Median Rate Q1 Q3
A1 11 1.0 x 10-3 9.2 x 10-4 1.2 x 10-3
A2a 44 1.0 x 10-3 9.1 x 10-4 1.1 x 10-3
A2b1 86 1.0 x 10-3 9.2 x 10-4 1.1 x 10-3
A2b2 60 9.9 x 10-4 8.9 x 10-4 1.1 x 10-3
A2b2 180 25 1.0 x 10-3 9.2 x 10-4 1.1 x 10-3
A2b2 111 287 1.0 x 10-3 8.9 x 10-4 1.2 x 10-3
hMPV-B
n Median Rate Q1 Q3
B1 193 7.8 x 10-4 6.6 x 10-4 9.6 x 10-4
B2 263 7.6 x 10-4 6.6 x 10-4 9.1 x 10-4
D
Effective Population Size, Ne
hMPV-A
hMPV-B
E
Evolutionary Rate (subst/site/year)
hMPV-A
hMPV-B
F
A2b2 sublineage G gene
n
A2b2 412
A2b2 180 282
A2b2 111 686
83/96
97.5/100
0.02
G
Independent duplications model
Duplication-deletion model
A2b2
A2b2 180
A2b2 111
180 nt
111 nt
162 nt
129 nt